Sign in to view content

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

John W. Kitchens, MD

Video
Published 2022

Related

Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2022
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Treatment Patterns and Vision Changes in Anti-VEGF Refractory Diabetic Macular Edema After Dexamethasone Implant in US Clinical Practice
Yasha S Modi, MD
On Demand Cases, Courses, and Papers
2021

Category: Diabetic Retinopathy

See more